INDV — Supernus, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1625297 ·
Last close
$36.28
Market Cap
$4.28B
52W High
$37.01
52W Low
$35.32
ADV30
4,869,435
Next earnings
2026-10-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 356,000,000 | 305,000,000 | 181,000,000 | 137,000,000 | 1,332,000,000 | 305,000,000 | 1,392,000,000 |
| Jun 2026 | 343,000,000 | 293,000,000 | 159,000,000 | 122,000,000 | 1,233,000,000 | 222,000,000 | 1,440,000,000 |
| Mar 2026 | 317,000,000 | 277,000,000 | 137,000,000 | 89,000,000 | 1,197,000,000 | 175,000,000 | 1,341,000,000 |
| Dec 2025 | 358,000,000 | 291,000,000 | 83,000,000 | 102,000,000 | 1,201,000,000 | 195,000,000 | 1,300,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-41,000,000
Investing CF
$-70,000,000
Financing CF
$-176,000,000
CapEx
$-71,000,000
Dividends Paid
—
Buybacks
$-302,000,000
EPS Diluted TTM
$2.79
As of
2026-11-01
Balance + Analyst (yfinance extras)
Retained Earnings
$-334,000,000
Inventory
$151,000,000
Receivables
$287,000,000
ST Investments
$0
EBIT TTM
$420,000,000
Pretax Income TTM
$393,000,000
Interest Exp TTM
$27,000,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,374,000,000
EBITDA
$652,000,000
Free Cash Flow
$227,124,992
Enterprise Value
$4,370,907,648
Total Cash
$305,000,000
Total Debt
$501,000,000
Shares Out
118,035,272
Trailing EPS
$2.79
Book Value
$-1.76
ROE
—
ROA
29.3%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,239,000,000 | 265,000,000 | 210,000,000 | 1,201,000,000 | 1,300,000,000 | -99,000,000 | -27,000,000 |
| Dec 2024 | 1,188,000,000 | 234,000,000 | 7,000,000 | 1,316,000,000 | 1,653,000,000 | -337,000,000 | 36,000,000 |
| Dec 2023 | 1,093,000,000 | 247,000,000 | -126,000,000 | 1,760,000,000 | 1,952,000,000 | -192,000,000 | -300,000,000 |
| Dec 2022 | 901,000,000 | 215,000,000 | -44,000,000 | 1,769,000,000 | 1,718,000,000 | 51,000,000 | -4,000,000 |
TTM Snapshot
Revenues TTM
$1,331,000,000
NetIncome TTM
$356,000,000
OpCashFlow TTM
—
Assets (Latest)
$1,233,000,000
Forward EPS
$4.51
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IONS | IONIS PHARMACEUTICALS INC | $4.49B | $26.96 | — |
| EWTX | Edgewise Therapeutics, Inc. | $4.60B | $42.04 | — |
| KNSA | Kiniksa Pharmaceuticals International, plc | $4.64B | $95.11 | — |
| GIKLY | Grifols SA | $4.69B | $5.55 | — |
| SLS | SELLAS Life Sciences Group, Inc. | $3.90B | $19.15 | — |
News headlines (Yahoo Finance, 1h cache)
Indivior Pharmaceuticals (INDV) Could Be 30% Undervalued On Its Turnaround Narrative
2026-10-30 22:20 · Yahoo
Indivior Pharmaceuticals (INDV) Shareholders Back Merger After Record Third Quarter
2026-10-30 05:15 · Yahoo
Indivior Pharmaceuticals Inc. (INDV) Beats Q3 Earnings and Revenue Estimates
2026-10-29 11:35 · Yahoo
Indivior Reports Third Quarter 2026 Financial Results
2026-10-29 11:00 · Yahoo
Updated Effective Date: Huron Consulting Group Set to Join S&P SmallCap 600
2026-10-28 21:43 · Yahoo
MSG Rangers and Huron Consulting Group Set to Join S&P SmallCap 600
2026-10-22 22:08 · Yahoo
Indivior to Report Third Quarter 2026 Financial Results
2026-10-19 12:30 · Yahoo
Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend
2026-09-17 11:00 · Yahoo
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
2026-09-14 13:30 · Yahoo
Indivior Pharmaceuticals Inc. (INDV) Down 5.3% Since Last Earnings Report: Can It Rebound?
2026-09-02 15:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.